Author Archives: Alice Melão, MSc

Cell Therapies Show Potential as Treatment for PAH, Review Finds

Regenerative cell therapy can induce significant improvements in key clinical features of pulmonary arterial hypertension (PAH) in animal models, a review study shows. The study’s findings suggest that such treatment may represent a suitable approach to treat PAH in humans. Still, further testing is necessary to demonstrate the safety and…

Neurological Problems Possible in Premature Babies with BPD-related PH, Study Finds

Pulmonary hypertension (PH) is associated with poorer neurodevelopmental outcome and impaired growth in the first two years of life for preterm infants with bronchopulmonary dysplasia, a study shows. The study, “Developmental outcomes of preterm infants with bronchopulmonary dysplasia-associated pulmonary hypertension at 18-24 months of corrected age,” was published…

Top 10 Pulmonary Hypertension Stories of 2018

Throughout the past year, Pulmonary Hypertension News has brought you information about important discoveries, treatment developments, clinical trials, and other events dealing with pulmonary hypertension (PH). As we look ahead to 2019, here are the 10 most-read stories of 2018, with a summary of their significance to PH patients, family…

CTEPH Software Receives FDA’s Breakthrough Device Designation

The U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to  software being developed by Bayer and Merck — known as MSD outside the U.S. and Canada — to help identify chronic thromboembolic pulmonary hypertension (CTEPH). CTEPH is a rare form of pulmonary hypertension thought to…